← Back to screener

NEOGENOMICS INC NEO

Rank #1955 · Nasdaq · $2.3B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
37.9
P/E
-25.7
P/B
2.27
ROE
-8.8%
Op. Margin
-18.2%
Debt Ratio
74%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -25.7x, P/B 2.27x. Ranks in the top 59% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -8.8%. Ranks in the top 78% of the universe.

Safety ★★★☆☆
Good

Debt ratio 74%. Ranks in the top 31% of the universe.

Growth ★★★★☆
Good

Revenue growth of 16.1% year over year. Ranks in the top 24% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–186
2012–$-0.0B$-0.0B$0.0B–448
2013–$-0.0B$-0.0B$0.0B–665
2014–$0.0B$0.0B$0.0B–309
2015–$0.0B$0.0B$0.0B–225
2016–$0.0B$0.0B$0.0B–521
2017–$-0.0B$-0.0B$0.1B–249
2018$0.2B$0.0B$-0.0B$0.2B0.967
2019$0.2B$0.0B$-0.0B$0.2B1.2114
2020$0.3B$0.0B$0.0B$0.2B3.6118
2021$0.4B$0.0B$0.0B$0.3B3.292
2022$0.4B$-0.0B$0.0B$0.5B-3.1150
2023$0.5B$-0.1B$-0.0B$0.7B-24.5107
2024$0.5B$-0.2B$-0.1B$1.1B-30.967
2025$0.6B$-0.1B$-0.1B$1.0B-18.274

← See the full screener